Abstracts Archive - Page 800 of 2607 - ACR Meeting Abstracts

Abstract Number: 1423 • ACR Convergence 2021
Ability of Soluble Immune Mediators and SLE-associated Autoantibody Specificities to Forecast Transition to Classified SLE and Inform a Lupus Classification Risk Immune Index
Melissa Munroe¹, Rufei Lu², Timothy Gross¹, George Tsokos³, Michael Keith⁴, John Harley⁵ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, OUHSC, Oklahoma City, OK, ³BIDMC, Boston, MA, ⁴Inova, Arlington, VA, ⁵US Department of Veterans Affairs Medical Center, Cincinnati, OH
Background/Purpose: SLE is a chronic autoimmune disease driven by immune dysregulation. We have previously identified patterns of disordered immunity present prior to and concurrent with…
Abstract Number: 1424 • ACR Convergence 2021
Secukinumab Treatment in Children and Adolescents with Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis: Efficacy and Safety Results from a Phase 3 Study
Hermine Brunner¹, Ivan Foeldvari², Ekaterina Alexeeva³, Nuray Ayaz⁴, Inmaculada Calvo Penads⁵, Ozgur Kasapcopur⁶, Vyacheslav Chasnyk⁷, Markus Hufnagel⁸, Zbigniew Zuber⁹, Grant Schulert¹, Seza Ozen¹⁰, Artem Popov¹¹, Athimalaipet Ramanan¹², Christiaan Scott¹³, Betul Sozeri¹⁴, Elena Zholobova¹⁵, Xuan Zhu¹⁶, Sarah Whelan¹⁷, Luminita Pricop¹⁸, Angelo Ravelli¹⁹, Alberto Martini²⁰, Daniel Lovell²¹ and Nicolino Ruperto²², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Hamburger Zentrum fuer Kinder- und Jugendrheumatologie, Hamburg, Germany, ³Scientific Center of Children Health of RAMS, Moscow, Russia, ⁴Istanbul University, İstanbul, Turkey, ⁵Hospital Universitario y Politécnico La Fe, Valencia, Spain, ⁶Istanbul University-Cerrahpasa, İstanbul, Turkey, ⁷Saint-Petersburg State Pediatric Medical Academy, Saint Petersburg, Russia, ⁸Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany, ⁹Paediatric Rheumatology International Trials Organisation (PRINTO), Lodz, Poland, ¹⁰Hacettepe University Medical Faculty, Ankara, Turkey, ¹¹Ural State Medical University, Yekaterinburg, Russia, ¹²University of Bristol, Bristol, United Kingdom, ¹³Paediatric Rheumatology, University of Cape Town, Cape Town, South Africa, ¹⁴University of Health Sciences, Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology, Istanbul, Turkey, ¹⁵First Moscow State Medical University n.a. I.M.Sechenov, Moscow, Russia, ¹⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁷Novartis, Dublin, Ireland, ¹⁸Novartis Pharmaceutical Corporation, East Hanover, NJ, ¹⁹Istituto Giannina Gaslini, Genoa, Italy, ²⁰IRCCS Istituto G. Gaslini, Università di Genova Pediatria II, Genova, Italy, ²¹Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, ²²IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy
Background/Purpose: Enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) are two conditions that represent pediatric correlates of axial spondyloarthritis (axSpA) and adult psoriatic arthritis (PsA),…
Abstract Number: 1425 • ACR Convergence 2021
Voclosporin for Lupus Nephritis: Interim Analysis of the AURORA 2 Extension Study
Amit Saxena¹, Christopher Mela² and Antonia Coeshall³, ¹NYU School of Medicine, New York, NY, ²Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, ³Aurinia Pharmaceuticals Inc., Rockville
Background/Purpose: Voclosporin, a novel calcineurin inhibitor (CNI), has been tested successfully in 2 pivotal trials in adult patients with lupus nephritis (LN). Previously reported results…
Abstract Number: 1426 • ACR Convergence 2021
Genotype and Transfusion Dependence Predicts Mortality in VEXAS Syndrome, a Newly Described Disease with Overlap Inflammatory and Hematologic Features
Marcela Ferrada¹, Sinisa Savic², Hugh Alessi³, Daniela Ospina⁴, Lorena Wilson⁵, Wendy Goodspeed⁶, Tannaz Kermani⁷, Kenneth Warrington⁸, Matthew Koster⁸, Bhavisha Patel⁹, Patrycja Hoffmann¹⁰, James Poulter¹¹, Rachel Tattersall¹², Amanda Ombrello¹, Christopher Duncan¹³, Elspeth Payne¹⁴, Karoline Krause¹⁵, Hanna Bonnekoh¹⁶, Daniel Kastner¹⁷, Peter Grayson¹⁸ and David Beck¹, ¹National Institutes of Health, Bethesda, MD, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ³National Institutes of Health, Bethesda, Maryland, ⁴NIH/NHGRI, Bethesda, MD, ⁵National Institutes of Health, Silver Spring, MD, ⁶National Institutes of Health (NIH), Bethesda, MD, ⁷University of California Los Angeles, Los Angeles, CA, ⁸Mayo Clinic, Rochester, MN, ⁹National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ¹⁰National Institutes of Health, Vienna, VA, ¹¹University of Leeds, Leeds, United Kingdom, ¹²Sheffield Teaching Hospitals NHS Foundation, Sheffield, United Kingdom, ¹³Translational and Clinical Research institute, Immunity and Inflammation Theme, Newcastle, United Kingdom, ¹⁴University College London, Cancer Institute, London, United Kingdom, ¹⁵Department of Dermatology and Allergy, Charité, Berlin, Germany, ¹⁶Department of Dermatology and Allergy, Charité, Berlin, United Kingdom, ¹⁷National Human Genome Research Institute, Bethesda, MD, ¹⁸National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a newly defined disease cause by myeloid-restricted somatic mutations in blood. Missense mutations at codon…
Abstract Number: 1427 • ACR Convergence 2021
Reduction of Cardiovascular Disease and Mortality versus Risk of New Onset Diabetes with Statin Use in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sophie Dell’Aniello², Sofia Pedro³, Kaleb Michaud⁴ and Samy Suissa⁵, ¹University of Nebraska Medical Center, Bellevue, NE, ²Center for Clinical Epidemiology, Lady Davis Research Institute - Jewish General Hospital, Montréal, QC, Canada, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Center for Clinical Epidemiology, Lady Davis Research Institute - Jewish General Hospital;Depts of Epidemiology and Biostatistics and of Medicine, McGill University, Montréal, QC, Canada
Background/Purpose: The risks of death and of type 2 diabetes mellitus (T2DM) are increased in RA mainly due to inflammation mediated accelerated cardiovascular disease (CVD)…
Abstract Number: 1428 • ACR Convergence 2021
Association Between Ongoing Glucocorticoid Use and Major Adverse Cardiovascular Events Among Veterans with Rheumatoid Arthritis
Beth Wallace¹, Yuqing Gao², Punyasha Roul³, Shirley Cohen-Mekelberg², Bryant England³, Ted Mikuls³, Daniel Clauw⁴, Wyndy Wiitala², Rodney Hayward⁵, Jeremy Sussman⁶ and Akbar Waljee⁵, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²VA Ann Arbor Healthcare System, Center for Clinical Management Research, Ann Arbor, MI, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Michigan, VA Ann Arbor Healthcare System, Center for Clinical Management Research, Ann Arbor, MI, ⁶University of Michigan; VA Ann Arbor Healthcare System; Center for Clinical Management Research, Ann Arbor, MI
Background/Purpose: A third of RA patients use long-term glucocorticoids (GCs) despite a known dose-dependent association with major adverse cardiovascular (CV) events (MACE). Prior work suggests…
Abstract Number: 1429 • ACR Convergence 2021
ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Diseases
Stacey Dillon, Lawrence Evans, Katherine Lewis, Jing Yang, Mark Rixon, Joe Kuijper, Daniel Demonte, Janhavi Bhandari, Steven Levin, Kayla Kleist, Sherri Mudri, Susan Bort, Daniel Ardourel, Michelle Seaberg, NinXin Wang, Chelsea Gudgeon, Russell Sanderson, Martin Wolfson, Jan Hillson, Pamela Holland and Stanford Peng, Alpine Immune Sciences, Seattle, WA
Background/Purpose: B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) are TNF superfamily members that bind TACI (transmembrane activator and CAML interactor), BCMA…
Abstract Number: 1430 • ACR Convergence 2021
Autoantibodies Stabilize Neutrophil Extracellular Traps in COVID-19
Yu Zuo¹, Srilakshmi Yalavarthi¹, Sherwin Navaz¹, Claire Hoy¹, Alyssa Harbaugh¹, Kelsey Gockman¹, Melanie Zuo¹, Jacqueline Madison¹, Hui Shi¹, Yogendra Kanthi² and Jason Knight¹, ¹University of Michigan, Ann Arbor, MI, ²NHLBI, NIH, Bethesda, MD
Background/Purpose: The release of neutrophil extracellular traps (NETs) by hyperactive neutrophils is recognized to play an important role in the thromboinflammatory milieu inherent to severe…
Abstract Number: 1431 • ACR Convergence 2021
Human TLR8 Leads to Fatal Anemia Due to Ineffective Erythropoiesis in Bone Marrow Erythroblastic Islands in Murine SLE
Naomi Maria¹, Julien Papoin¹, Chirag Raparia¹, Zeguo Sun², Shani Martinez¹, Weijia Zhang², Lionel Blanc¹ and Anne Davidson¹, ¹Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ²Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: There are multiple causes of anemia in SLE including hemolysis, inflammation, renal insufficiency and, more rarely, microangiopathy, hemophagocytosis and bone marrow insufficiency. One cause…
Abstract Number: 1432 • ACR Convergence 2021
Modulation of Auto-Inflammation with a Novel Selective Cyclic GMP-AMP Synthase (cGAS) Inhibitor in a Trex1-/- Model
Kelly Pike¹, Alexandre Caron¹, Emilie Bérubé¹, Ramsay Beveridge¹, Marc-Oliver Boily¹, Jason Burch¹, Valerie Dumais¹, Nadine Fradet¹, Samuel Gaudreault¹, Daniel McKay¹, Marianne Raymond¹, Eleftheria Seliniotakis¹, Daniel Sietsema³, Alexander Skeldon¹, Miguel St.-Onge¹, Li Wang² and Michael Crackower², ¹Ventus Therapeutics, Montréal, QC, Canada, ²Ventus Therapeutics, Waltham, MA

Background/Purpose: The detection of viral nucleic acids (NA) elicits a transient type I interferon (IFN) response central to antiviral immunity. Chronic type I IFN responses…
Abstract Number: 1433 • ACR Convergence 2021
Endothelium-protective, Histone-neutralizing Properties of the Polyanionic Agent Defibrotide
Hui Shi¹, Alex Gandhi¹, Stephanie Smith¹, Qiuyu Wang¹, Diane Chiang¹, Srilakshmi Yalavarthi¹, Ramadan Ali², Chao Liu¹, Gautam Sule¹, Eliza Pei-Suen Tsou¹, Yu Zuo¹, Yogendra Kanthi³, Jiandie Lin¹, James Morrissey¹ and Jason Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arobr, MI, ³NHLBI, NIH, Bethesda, MD
Background/Purpose: Neutrophil-mediated activation of the endothelium plays a role in the pathogenesis of diverse disease states ranging from autoimmunity to cancer to COVID-19. Neutralization of…
Abstract Number: 1434 • ACR Convergence 2021
Multiomic Study of Skin, Peripheral Blood and Serum: Is Serum Proteome a Reflection of Disease Process at the End-Organ Level in Systemic Sclerosis?
Victor Farutin¹, Elma Kurtagic², Joel Pradines³, Ishan Capila³, Maureen Mayes⁴, Minghua Wu⁵, Anthony Manning³ and Shervin Assassi⁶, ¹Janssen R&D, LLC, Watertown, MA, ²Janssen R&D, LLC, Cambridge, ³Momenta Pharmaceuticals, Inc., Cambridge, MA, ⁴Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁵University of Texas Health Science Center at Houston, Houston, TX, ⁶University of Texas McGovern Medical School at Houston, Houston, TX
Background/Purpose: Discovery of biomarkers in systemic sclerosis (SSc) represents an unmet clinical need. Samples from prominently affected fibrotic end-organs such as lung and skin are…
Abstract Number: 1435 • ACR Convergence 2021
Identification of Distinct Fibroblast Populations in Systemic Sclerosis 3D Skin Tissues with Single Cell Omics
Noelle Kosarek¹, Heetaek Yang², Fred W. Kolling³, Tamar Abel⁴, Mengqi Huang⁵, Avi Smith⁶, Jonathan Garlick⁶, Patricia A. Pioli² and Michael L. Whitfield⁷, ¹Dartmouth Geisel School of Medicine, Hartford, VT, ²Geisel School of Medicine, Hanover, NH, ³Centers for Quantitative Biology, Hanover, ⁴Geisel School of Medicine, West Lebanon, NH, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶Tufts University School of Dental Medicine, Boston, MA, ⁷Geisel School of Medicine, Lebanon, NH
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by skin and internal organ fibrosis, vascular abnormalities, and autoantibody formation. Single cell genomics studies…
Abstract Number: 1436 • ACR Convergence 2021
Expanded PD-1hi CXCR5- HLA-DR+ T Cells Is Associated with Interstitial Lung Disease in Systemic Sclerosis
Mehreen Elahee¹, Alisa Mueller², Runci Wang³, Ye Cao², Andrea Fava⁴, Paul Dellaripa², Francesco Boin⁵ and Deepak Rao², ¹Brigham and Women's Hospital, Natick, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospital, Boston, MA, ⁴Johns Hopkins University, Baltimore, MD, ⁵Cedars-Sinai Medical Center, West Hollywood, CA
Background/Purpose: Interstitial lung disease (ILD) is the major cause of morbidity and mortality in systemic sclerosis (SSc), yet there are few biomarkers to identify pathologic…
Abstract Number: 1437 • ACR Convergence 2021
Fat and Fibrosis: A Novel Developmental Gene in Systemic Sclerosis
Nancy Wareing¹, Brian Skaug², Minghua Wu³, Scott Collum¹, Cory Wilson¹, Lucy Revercomb⁴, Marka Lyons⁵, Weizhen Bi⁶, Tingting Mills¹, Julio Charles⁵, Shervin Assassi¹ and Harry Karmouty-Quintana¹, ¹University of Texas McGovern Medical School at Houston, Houston, TX, ²University of Texas McGovern Medical School Houston, Houston, TX, ³University of Texas Health Science Center at Houston, Houston, TX, ⁴Rice University, Houston, TX, ⁵Division of Rheumatology, University of Texas McGovern Medical School at Houston, Houston, TX, ⁶McGovern Medical School at UTHealth, Houston, TX
Background/Purpose: Early loss of skin-associated adipose tissue and concomitant replacement by extracellular matrix is a hallmark of systemic sclerosis (SSc). However, the contribution of adipose…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].